ClinicalTrials.gg
CompletedNCT04725188Updated Aug 15, 2025Results posted

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

A Phase 2 interventional study of Pembrolizumab/Vibostolimab coformulation and Docetaxel in Metastatic Non Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 95 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
27th of 188
255 · median 50
Started
2021
with 3 others
Phase 2
125 of 198
9 open now
Registered
178th of 198
by date

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 27th largest by enrollment of the 188 interventional ones that give a count, is one of 4 that started in 2021, is one of 125 in phase 2, and was the 178th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose of this study is to compare pembrolizumab/vibostolimab coformulation (MK-7684A) plus docetaxel or pembrolizumab/vibostolimab coformulation to normal saline placebo plus docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti- programmed cell death 1 (PD-1)/ programmed cell death ligand 1(PD-L1) monoclonal antibody (mAb). MK-7684A is a coformulation product of pembrolizumab/vibostolimab. The dual primary hypotheses of the study are pembrolizumab/vibostolimab coformulation plus docetaxel and pembrolizumab/vibostolimab coformulation is superior to normal saline placebo plus docetaxel with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Read the detailed description

Participants may receive additional 17 cycles of pembrolizumab/vibostolimab (each cycle length = 21 days) for an additional 1 year of treatment as second course phase at investigator's discretion.

03

Conditions studied

  • Metastatic Non Small Cell Lung Cancer

Keywords

  • Programmed Cell Death Receptor 1 (PD-1)
  • Programmed Cell Death Receptor Ligand 1 (PD-L1)
  • Programmed Cell Death Receptor Ligand 2 (PD-L2)
  • PD-1
  • PDL1
  • PD-L1
  • PD-L2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
  • Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or reactive oxygen species (ROS) 1 directed therapy is not indicated as primary therapy
  • Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 ()/ programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies

    • Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
  • Has PD as determined by the investigator after platinum doublet chemotherapy for metastatic disease
  • Has defined as at least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI), based on Version 1.1 (RECIST 1.1)
  • Has provided tumor tissue for PD-L1 biomarker analysis from an or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
  • Has a of at least 3 months
  • Has an (ECOG) Performance Status of 0 to 1 assessed within 7 days prior to randomization
  • Male participants randomized to docetaxel are eligible to participant if they agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) must agree to follow guidance as per study protocol unless confirmed to be azoospermic during the intervention period and for at least 180 days after the last dose of docetaxel
  • Female participants must be not pregnant, not breastfeeding, and not be a woman of (WOCBP). A WOCBP is eligible is she agrees to either use contraception, or be abstinent from heterosexual intercourse during the intervention period and for ≥120 days after the last dose of study intervention. If a WOCBP is randomized to docetaxel, she agrees not to donate eggs and either uses contraception or be abstinent from heterosexual intercourse during the treatment period and for ≥180 days after the last dose of docetaxel
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has known active or untreated central nervous system (CNS) and/or carcinomatous meningitis
  • Has a known history of an additional , except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy
  • Has received docetaxel as monotherapy or in combination with other therapies
  • Has received previous treatment with another agent targeting the T-cell immunoreceptor with immunoglobulin [Ig] and immunoreceptor tyrosine-based inhibitory motif [ITIM] domains (TIGIT) pathway
  • Has received radiotherapy within 2 weeks of start of study intervention. One week is permitted for palliative radiation to non-CNS disease
  • Has received a live or within 30 days before the first dose of study intervention
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks before the first dose of study intervention
  • Has severe (≥Grade 3) to docetaxel or pembrolizumab/vibostolimab coformulation and/or any of its
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days before the first dose of study intervention
  • Has interstitial lung disease, or history of pneumonitis requiring steroids for treatment
  • Has known history of active (HIV), or
  • Has had an allogenic tissue/solid organ transplant
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\^2 via IV infusion Q3W. Each cycle will be 21 days.

    Biological: Pembrolizumab/Vibostolimab coformulation · Drug: Docetaxel

  • Experimental
    Arm 2: Pembrolizumab/Vibostolimab coformulation

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle will be 21 days.

    Biological: Pembrolizumab/Vibostolimab coformulation

  • Active comparator
    Arm 3: Placebo + Docetaxel

    Participants receive normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\^2 IV infusion Q3W. Each cycle will be 21 days.

    Drug: Docetaxel · Drug: Placebo

Interventions

  • BiologicalPembrolizumab/Vibostolimab coformulation

    Drug page: Vibostolimab/Pembrolizumab MK-7684A

    Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.

    Also known as: MK-7684A

  • Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.

    Also known as: Taxotere

  • DrugPlacebo

    Normal saline IV infusion Q3W up to approximately 2 years

This study also gives Pembrolizumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment

    PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.

    Time frame: Up to approximately 21 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment

    ORR is defined as the percentage of participants who have a confirmed complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.

    Time frame: Up to approximately 21 months

  2. Overall Survival (OS)

    OS is defined as the time from randomization to the date of death due to any cause.

    Time frame: Up to approximately 21 months

  3. Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment

    For participants who demonstrate a confirmed CR (Disappearance of all target lesions) or confirmed PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR is presented.

    Time frame: Up to approximately 21 months

  4. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported here.

    Time frame: Up to approximately 39 months

  5. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.

    Time frame: Up to approximately 27 months

07

Results

Posted Apr 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + Docetaxel
Started878385
Treated858383
Completed000
Not completed878385
Withdrew: Death726976
Withdrew: Lost to follow-up101
Withdrew: Withdrawal by subject221
Withdrew: Sponsor decision12127

Outcome measures

PrimaryProgression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment

PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.

Time frame:
Up to approximately 21 months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment
MonthsArm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + Docetaxel
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment5.6 (3.9 to 6.8)2.7 (1.8 to 4.0)3.2 (2.8 to 5.7)
Statistical analysis
  • Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel vs Arm 3: Placebo + Docetaxel · Regression, Cox · p = 0.0910 · Hazard ratio (hr): 0.77 · 95% CI 0.53 to 1.13
  • Arm 2: Pembrolizumab/Vibostolimab Coformulation vs Arm 3: Placebo + Docetaxel · Regression, Cox · p = 0.9622 · Hazard ratio (hr): 1.40 · 95% CI 0.96 to 2.02
SecondaryObjective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment

ORR is defined as the percentage of participants who have a confirmed complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.

Time frame:
Up to approximately 21 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment
Percentage of participantsArm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + Docetaxel
Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment29.9 (20.5 to 40.6)6.0 (2.0 to 13.5)15.3 (8.4 to 24.7)
Statistical analysis
  • Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel vs Arm 3: Placebo + Docetaxel · Miettinen & Nurminen method · p = 0.0113 · Difference in percentage: 14.7 · 95% CI 2.1 to 26.9
  • Arm 2: Pembrolizumab/Vibostolimab Coformulation vs Arm 3: Placebo + Docetaxel · Miettinen & Nurminen method · p = 0.9750 · Difference in percentage: -9.4 · 95% CI -19.6 to 0.0
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to the date of death due to any cause.

Time frame:
Up to approximately 21 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + Docetaxel
Overall Survival (OS)10.2 (8.6 to 14.9)7.5 (5.2 to 13.4)8.8 (6.4 to 11.1)
Statistical analysis
  • Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel vs Arm 3: Placebo + Docetaxel · Regression, Cox · p = 0.0943 · Hazard ratio (hr): 0.76 · 95% CI 0.50 to 1.15
  • Arm 2: Pembrolizumab/Vibostolimab Coformulation vs Arm 3: Placebo + Docetaxel · Regression, Cox · p = 0.5974 · Hazard ratio (hr): 1.05 · 95% CI 0.70 to 1.58
SecondaryDuration of Response (DOR) Per RECIST 1.1 by BICR Assessment

For participants who demonstrate a confirmed CR (Disappearance of all target lesions) or confirmed PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR is presented.

Time frame:
Up to approximately 21 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment
MonthsArm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + Docetaxel
Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment6.5 (5.3 to 10.7)NA (2.8 to NA)NA (3.0 to NA)
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported here.

Time frame:
Up to approximately 39 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsArm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + Docetaxel
Number of Participants Who Experienced an Adverse Event (AE)857682
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.

Time frame:
Up to approximately 27 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsArm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + Docetaxel
Number of Participants Who Discontinued Study Treatment Due to an AE421224

Adverse events

Collected over Up to approximately 39 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab/Vibostolimab Coformulation + Docetaxel74/87 (85.1%)48/85 (56.5%)83/85 (97.6%)
Pembrolizumab/Vibostolimab Coformulation70/83 (84.3%)26/83 (31.3%)67/83 (80.7%)
Placebo + Docetaxel77/85 (90.6%)37/83 (44.6%)76/83 (91.6%)
Most frequent serious events
Showing 10 of 123
Most frequent serious events
EventPembrolizumab/Vibostolimab Coformulation + DocetaxelPembrolizumab/Vibostolimab CoformulationPlacebo + Docetaxel
PneumoniaInfections and infestations7/853/8310/83
Febrile neutropeniaBlood and lymphatic system disorders3/850/833/83
AnaemiaBlood and lymphatic system disorders3/851/832/83
DiarrhoeaGastrointestinal disorders3/851/832/83
COVID-19Infections and infestations3/851/831/83
Septic shockInfections and infestations3/850/830/83
Hip fractureInjury, poisoning and procedural complications3/850/830/83
DeathGeneral disorders1/851/832/83
COVID-19 pneumoniaInfections and infestations0/852/830/83
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/851/832/83
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPembrolizumab/Vibostolimab Coformulation + DocetaxelPembrolizumab/Vibostolimab CoformulationPlacebo + Docetaxel
DiarrhoeaGastrointestinal disorders31/8510/8323/83
PruritusSkin and subcutaneous tissue disorders31/8517/834/83
AnaemiaBlood and lymphatic system disorders30/8512/8328/83
AstheniaGeneral disorders26/8515/8324/83
FatigueGeneral disorders26/8510/8323/83
NauseaGastrointestinal disorders24/8511/8322/83
AlopeciaSkin and subcutaneous tissue disorders24/852/8320/83
RashSkin and subcutaneous tissue disorders22/8515/837/83
Decreased appetiteMetabolism and nutrition disorders21/8511/8319/83
ConstipationGastrointestinal disorders20/856/839/83

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + DocetaxelTotal
Mean64.7 ± 8.866.0 ± 7.465.8 ± 8.065.5 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + DocetaxelTotal
Female27232474
Male606061181
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + DocetaxelTotal
Hispanic or Latino129627
Not Hispanic or Latino626865195
Unknown or Not Reported1361433
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + DocetaxelTotal
American Indian or Alaska Native0000
Asian11141035
Native Hawaiian or Other Pacific Islander1001
Black or African American0112
White626360185
More than one race0000
Unknown or Not Reported1351432
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline(Participants)Arm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + DocetaxelTotal
Tumor proportion score (TPS) ≥50%15141342
TPS 1-49%34193588
TPS <1%374534116
Unknown (Not evaluable due to <100 viable tumor cells)1539
Predominant Tumor Histology
Predominant Tumor Histology(Participants)Arm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + DocetaxelTotal
Squamous26203480
Non-squamous616351175
Prior Lines of Therapy
Prior Lines of Therapy(Participants)Arm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + DocetaxelTotal
1584952159
225282679
314712
41203
≥52002
Sequence of Prior Anti-Programmed Cell Death Receptor 1 (PD-1)/PD-L1
Sequence of Prior Anti-Programmed Cell Death Receptor 1 (PD-1)/PD-L1(Participants)Arm 1: Pembrolizumab/Vibostolimab Coformulation + DocetaxelArm 2: Pembrolizumab/Vibostolimab CoformulationArm 3: Placebo + DocetaxelTotal
Immediate Prior Therapy727072214
Not the Immediate Prior Therapy15131341

1 further baseline measures are reported on the registry.

08

Study locations

95 sites
  • Cedars-Sinai Medical Center ( Site 2522)
    Los Angeles, California 90048, United States
  • Illinois Cancer Care ( Site 2534)
    Peoria, Illinois 61615, United States
  • Baptist Health Lexington-Research ( Site 2502)
    Lexington, Kentucky 40503, United States
  • University of Maryland ( Site 2528)
    Baltimore, Maryland 21201, United States
  • Hattiesburg Clinic Hematology/Oncology ( Site 2511)
    Hattiesburg, Mississippi 39401, United States
  • Mercy Research - Cancer and Hematology Center ( Site 2535)
    Springfield, Missouri 65804, United States
  • Mercy Research - David C. Pratt Cancer Center ( Site 2532)
    St Louis, Missouri 63109, United States
  • Montefiore- Einstein Center for Cancer Care-Oncology ( Site 2509)
    The Bronx, New York 10461, United States
  • University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 2526)
    Cincinnati, Ohio 45219, United States
  • St Francis Cancer Center-Research Office ( Site 2531)
    Greenville, South Carolina 29607, United States
  • Centro de Oncología e Investigación de Buenos Aires ( Site 0008)
    Berazategui, Buenos Aires B1884BBF, Argentina
  • Hospital Privado de Comunidad ( Site 0004)
    Mar del Plata, Buenos Aires 7600, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0002)
    Mar del Plata, Buenos Aires 7600, Argentina
  • Instituto de Oncología de Rosario ( Site 0003)
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Hospital Privado Universitario de Córdoba ( Site 0001)
    Córdoba, 5016, Argentina
  • Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0005)
    La Rioja, F5300COE, Argentina
  • Canberra Hospital ( Site 0104)
    Canberra, Australian Capital Territory 2605, Australia
  • Gold Coast University Hospital-Clinical Trials Service ( Site 0106)
    Southport, Queensland 4215, Australia
  • Fiona Stanley Hospital-Medical Oncology ( Site 0102)
    Murdoch, Western Australia 6150, Australia
  • Medizinische Universität Graz ( Site 0201)
    Graz, Styria 8036, Austria
  • Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0203)
    Linz, Upper Austria 4020, Austria
  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0204)
    Vienna, 1210, Austria
  • AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0333)
    Mechelen, Antwerpen 2800, Belgium
  • UZ Brussel ( Site 0336)
    Brussels, Bruxelles-Capitale, Region de 1090, Belgium
  • Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0337)
    Charleroi, Hainaut 6000, Belgium
  • Jessa Ziekenhuis-Pulmonology & Thoracic Oncology ( Site 0338)
    Hasselt, Limburg 3500, Belgium
  • AZ Nikolaas ( Site 0334)
    Sint-Niklaas, Oost-Vlaanderen 1932, Belgium
  • Hospital Nossa Senhora da Conceição ( Site 0403)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 0400)
    São Paulo, São Paulo 01246-000, Brazil
  • Centro de Tratamento de Tumores Botafogo - CTTB-Pesquisa Clínica ( Site 0402)
    Rio de Janeiro, 22250-905, Brazil
  • Hospital Paulistano ( Site 0406)
    São Paulo, 01321-000, Brazil
  • Rigshospitalet ( Site 0702)
    Copenhagen, Capital Region 2100, Denmark
  • Odense Universitetshospital ( Site 0700)
    Odense, Region Syddanmark 5000, Denmark
  • Sygehus Soenderjylland-Kraeftambulatoriet ( Site 0705)
    Sønderborg, Region Syddanmark 6400, Denmark
  • Oulun yliopistollinen sairaala ( Site 0902)
    Oulu, North Ostrobothnia 90220, Finland
  • Tampereen yliopistollinen sairaala-Oncology ( Site 0906)
    Tampere, Pirkanmaa 33520, Finland
  • Vaasan Keskussairaala ( Site 0903)
    Vaasa, Pohjanmaa 65130, Finland
  • Turku University Hospital-The Department of Pulmonary Medicine ( Site 0905)
    Turku, Southwest Finland 20520, Finland
  • Nouvel Hôpital Civil (NHC) ( Site 1000)
    Strasbourg, Alsace 67000, France
  • Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1009)
    Bordeaux, Aquitaine 33000, France
  • Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre ( Site 1006)
    Caen, Calvados 14033, France
  • CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 1008)
    Toulouse, Haute-Garonne 31059, France
  • Clinique Ambroise Paré ( Site 1007)
    Beuvry, Pas-de-Calais 62660, France
  • Centre Hospitalier du Mans ( Site 1002)
    Le Mans, Sarthe 72037, France
  • Gustave Roussy ( Site 1005)
    Villejuif, Val-de-Marne 94800, France
  • HIA Sainte Anne ( Site 1003)
    Toulon, Var 83800 Cedex 9, France
  • Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1004)
    Avignon, Vaucluse 84000, France
  • Onkologie Ravensburg ( Site 1104)
    Ravensburg, Baden-Wurttemberg 88212, Germany
  • Klinikverbund Allgaeu gGmbH ( Site 1109)
    Immenstadt im Allgäu, Bavaria 87509, Germany
  • Helios Dr. Horst Schmidt Kliniken ( Site 1108)
    Wiesbaden, Hesse 65199, Germany
  • Universitätsklinikum Bonn ( Site 1111)
    Bonn, North Rhine-Westphalia 53127, Germany
  • Helios Klinikum Emil von Behring Berlin-Zehlendorf ( Site 1106)
    Berlin, 14165, Germany
  • Soroka Medical Center ( Site 1202)
    Beersheba, 8410101, Israel
  • Rambam Health Care Campus-Oncology ( Site 1203)
    Haifa, 3109601, Israel
  • Shaare Zedek Medical Center-Oncology ( Site 1206)
    Jerusalem, 9103102, Israel
  • Sourasky Medical Center ( Site 1205)
    Tel Aviv, 6423906, Israel
  • Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1307)
    Rome, Lazio 00184, Italy
  • Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1308)
    Naples, Napoli 80131, Italy
  • CRO-IRCCS-medical oncology ( Site 1304)
    Aviano, Pordenone 33081, Italy
  • Azienda Sanitaria Ospedaliera S Luigi Gonzaga-Oncologia Polmonare ( Site 1300)
    Orbassano, Torino 10043, Italy
  • Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1306)
    Florence, Tuscany 50134, Italy
  • Ospedale San Raffaele-Oncologia Medica ( Site 1305)
    Milan, 20132, Italy
  • Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1301)
    Milan, 20141, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1303)
    Roma, 00168, Italy
  • Hospital Sultan Ismail ( Site 1503)
    Johor Bahru, Johor 81100, Malaysia
  • University Malaya Medical Centre ( Site 1501)
    Lembah Pantai, Kuala Lumpur 59100, Malaysia
  • Hospital Tengku Ampuan Afzan ( Site 1500)
    Kuantan, Pahang 25100, Malaysia
  • Beacon Hospital Sdn Bhd ( Site 1504)
    Petaling Jaya, Selangor 46050, Malaysia
  • Przychodnia Lekarska KOMED ( Site 1704)
    Konin, Greater Poland Voivodeship 62-500, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (
    Saint Petersburg, Leningradskaya Oblast' 190020, Russia
  • Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 1911)
    Saint Petersburg, Leningradskaya Oblast' 198255, Russia
  • Moscow Clinical Research Center-Chemotherapy department ( Site 1910)
    Moscow, Moscow 111123, Russia
  • Central Clinical Hospital of the Presidential Administrative Department ( Site 1902)
    Moscow, Moscow 121359, Russia
  • Hadassah Medical-Oncology department ( Site 1912)
    Moscow, Moscow Oblast 121205, Russia
  • Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 1909)
    Nizhny Novgorod, Nizhny Novgorod Oblast 603081, Russia
  • Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary ( Site 1908)
    Omsk, Omsk Oblast 644013, Russia
  • GBUZ LOKB-Oncology department #1 ( Site 1905)
    Saint Petersburg, Sankt-Peterburg 194291, Russia
  • N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Seoul National University Bundang Hospital ( Site 2003)
    Seongnam, Kyonggi-do 13620, South Korea
  • The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2005)
    Suwon, Kyonggi-do 16247, South Korea
  • Chungbuk National University Hospital-Internal medicine ( Site 2004)
    Cheongju-si, North Chungcheong 28644, South Korea
  • Asan Medical Center-Oncology ( Site 2000)
    Songpagu, Seoul 05505, South Korea
  • HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
    Barcelona, Catalonia 08036, Spain
  • Hospital de la Santa Creu i Sant Pau-Oncología Médica ( Site 2102)
    Barcelona, Catalonia 08041, Spain
  • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2101)
    Madrid, 28009, Spain
  • Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 2103)
    Seville, 41014, Spain
  • Ospedale Regionale Bellinzona e Valli ( Site 2203)
    Bellinzona, Canton Ticino 6500, Switzerland
  • Chang Gung Memorial Hospital at Kaohsiung ( Site 2303)
    Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan
  • Taichung Veterans General Hospital-Chest ( Site 2307)
    Taichung, 40705, Taiwan
  • NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 2302)
    Tainan, 704, Taiwan
  • National Taiwan University Hospital-Oncology ( Site 2304)
    Taipei, 10002, Taiwan
  • Mackay Memorial Hospital-Chest Medicine ( Site 2305)
    Taipei, 10449, Taiwan
  • Chulalongkorn University ( Site 2403)
    Bangkok, Bangkok 10330, Thailand
  • Faculty of Medicine Siriraj Hospital ( Site 2400)
    Bangkok, Bangkok 10700, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jan 2023, 21 months.

Results were first posted in Apr 2024, 1 year 2 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Jan 26, 2021
StartActual
Apr 20, 2021
Primary completionActual
Jan 26, 2023
CompletionActual
Oct 17, 2024
Results first posted
Apr 2, 2024
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04725188
Responsible party
Sponsor
First posted
Jan 26, 2021
Start date
Apr 20, 2021
Primary completion
Jan 26, 2023
Completion
Oct 17, 2024
Results posted
Apr 2, 2024
Last update
Aug 15, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vibostolimab/Pembrolizumab MK-7684A · Docetaxel

Start the discussion